Medically reviewed by the Celva medical team · June 2026
Results don't
arrive in week one.
The most common misunderstanding about MSC therapy is what change should look like at two weeks, four weeks, and four months. A plain reading of how the response actually unfolds.
Normal to feel nothing yet. Paracrine signaling is slow, not pharmacologic.
Where meaningful change typically emerges. Not dramatic, steady.
Where best-achieved outcomes usually land for qualifying candidates.
MSCs are slow ,
and that's expected.
Mesenchymal stem cells don't act like a drug. They modulate the joint environment through signaling molecules over weeks to months. Meaningful response cannot happen in week one.
The mechanism is paracrine: the cells release bioactive molecules that modify inflammation, support resident tissue biology, and influence the local environment. That process unfolds over time.
A slower response curve also means a more durable one. When change arrives at three to six months, it tends to hold rather than spike-and-fade.
No dramatic overnight relief. No "I walked out and felt new." That's not how this mechanism works. If a clinic promises rapid relief, that's a red flag worth pausing on.
The realistic
response curve.
Soreness, joint protected
Soreness at the injection site. Ice, acetaminophen as needed. No NSAIDs, they blunt the response. Stay off the joint with very limited activity for the first seven to ten days, then begin a slow, graded build over the following weeks.
The quiet phase
Baseline pain largely unchanged. Normal. Do not interpret silence as failure.
First meaningful signal
Morning stiffness reduces. Sleep improves. Activities that had been avoided start returning, quietly at first.
Measurable function
KOOS / HOOS / ASES / ODI scores improve by around four months for most responders. This is the window where the shift becomes legible.
Peak window
Best-achieved relief for most responders. Some patients benefit from a booster at six months. Others plateau and hold.
Durability
The therapeutic effect persists long after the cells have done their work. Duration varies by indication, tissue environment, and individual response. The physician team discusses what's realistic for your case during review.
The most honest way to evaluate progress is not week-over-week but against your three-month-prior self. Gradual change is easy to miss in real-time.
We score response on standardized scales at baseline, then at scheduled follow-up reads (4, 8, and 12 months for most joints; 6 and 12 for the slower-responding spine and foot). Structured measurement, not "how do you feel today."
This curve is drawn for the peripheral joints (hip, knee, shoulder, hands, feet). A spine or disc injection runs slower still, with the meaningful shift often closer to three to six months. And almost every injection patient also receives a systemic IV, recommended by the medical team, which follows its own faster sleep-and-energy curve.
Signals of
response.
Response doesn't announce itself in pain relief alone. The leading indicators are subtler, and often show up before the VAS score moves.
The patients who end up with the best outcomes usually notice these shifts between weeks four and twelve. Track them rather than just tracking pain.
Morning stiffness reduces
The first sixty seconds of moving in the morning. This often shifts before pain with activity does.
Sleep improves
Reduced night-pain awakening. Patients sleeping through the night for the first time in months.
NSAID use drops
Patients reach for ibuprofen less frequently. Often unconscious, noticed when the bottle lasts longer.
Avoided activities return
The hike, the yoga class, the stairs, the bike. The clearest functional signal.
When response
doesn't show.
Not every patient responds. A subset of candidates, even well-screened ones, see limited improvement at the six-month mark. This is real and we talk about it directly.
When a six-month review shows a flat response, the next conversation is about what that means: candidacy for a booster, re-evaluation for surgical consultation, or a combination of both.
No outcome is guaranteed. Our clinical follow-up shows meaningful improvement in many qualifying candidates, and a minority don't respond. We structure follow-up specifically to identify non-response early, not to paper over it.
Timeline
questions.
Q.01I haven't felt anything at week three. Is it working?
Q.02When is the earliest I could notice change?
Q.03Does taking NSAIDs during recovery hurt the response?
Q.04What if I plateau at three months?
Keep
reading.
See if the curve
applies to you.
Timeline expectations only matter once candidacy is confirmed. Your first call is with a Celva patient coordinator; Celva's medical team reads your imaging and tells you plainly what's reasonable to expect for your case.